tazemetostat
Showing 1 - 25 of 40
T-cell Lymphoma, CLL/SLL Trial in Birmingham (Tazemetostat, Acalabrutinib and Tazemetostat)
Not yet recruiting
- T-cell Lymphoma
- CLL/SLL
- Tazemetostat
- Acalabrutinib and Tazemetostat
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Aug 11, 2023
Peripheral Nerve Sheath Tumor Trial in Gainesville (Tazemetostat)
Recruiting
- Peripheral Nerve Sheath Tumor
- Tazemetostat
-
Gainesville, FloridaUniversity of Florida
Jan 4, 2023
Relapsed/Refractory Lymphoma Trial in Shanghai (tazemetostat, HMPL-689)
Not yet recruiting
- Relapsed/Refractory Lymphoma
- tazemetostat
- HMPL-689
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiaotong University School of Medicine
Feb 2, 2023
Solid Tumor, ARID1A Gene Mutation Trial in Greenville (Tazemetostat)
Suspended
- Solid Tumor
- ARID1A Gene Mutation
- Tazemetostat
-
Greenville, South CarolinaPrisma Health Cancer Institute
Jan 10, 2023
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in New York (Venetoclax, Tazemetostat)
Not yet recruiting
- Lymphoma, Non-Hodgkin
- +2 more
- Venetoclax
- Tazemetostat
-
New York, New YorkWeill Cornell Medicine/NewYork-Presberteryian Hospital
Jan 18, 2023
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Boston (TAZEMETOSTAT, Zandelisib)
Not yet recruiting
- Relapsed Follicular Lymphoma
- Refractory Follicular Lymphoma
- TAZEMETOSTAT
- Zandelisib
-
Boston, Massachusetts
- +1 more
Oct 28, 2022
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Trial in Isehara, Chuo-ku (tazemetostat)
Completed
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- Tazemetostat
-
Isehara, Kanagawa, Japan
- +1 more
Apr 6, 2022
Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (Tazemetostat, Pembrolizumab)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Tazemetostat
- Pembrolizumab
-
Saint Louis, MissouriWashington University School of Medicine
Oct 26, 2022
Relapsed/Refractory Follicular Lymphoma With EZH2 Trial in Shanghai (Tazemetostat)
Not yet recruiting
- Relapsed/Refractory Follicular Lymphoma With EZH2
- Tazemetostat
-
Shanghai, Shanghai, ChinaShanghai Cancer Center
Jul 20, 2022
Recurrent DLBCL Germinal Center B-Cell Type, Recurrent Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma Trial (Belinostat,
Not yet recruiting
- Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- +5 more
- Belinostat
- +2 more
- (no location specified)
Dec 2, 2022
Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors, SMARCA4-deficient Primary CNS Malignant
Recruiting
- Atypical Teratoid Rhabdoid Tumor
- +6 more
- Tazemetostat
- +2 more
-
Boston, Massachusetts
- +1 more
Jan 23, 2023
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer Trial in Boston (Talazoparib, Tazemetostat)
Recruiting
- Metastatic Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- Talazoparib
- Tazemetostat
-
Boston, Massachusetts
- +1 more
Jul 18, 2022
Non Small Cell Lung Cancer Trial in West Los Angeles (Tazemetostat)
Not yet recruiting
- Non Small Cell Lung Cancer
- Tazemetostat
-
West Los Angeles, CaliforniaVA Greater Los Angeles Healthcare System, West Los Angeles, CA
Jul 21, 2022
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Duarte (Tazemetostat, Ublituximab, Umbralisib)
Not yet recruiting
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Tazemetostat
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jul 31, 2022
Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma Trial (Tazemetostat)
Temporarily not available
- Epithelioid Sarcoma (Ex-US Only)
- +19 more
- Tazemetostat
- (no location specified)
Oct 17, 2022
Relapsed/Refractory Trial in Santa Fe (Tafasitamab, Lenalidomide, Tazemetostat)
Recruiting
- Relapsed/Refractory
- Tafasitamab
- +8 more
-
Santa Fe, CaliforniaCalifornia Cancer Associates For Research And Excellence, cCARE
Feb 23, 2022
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome Trial (Tazemetostat)
Withdrawn
- COVID-19 Acute Respiratory Distress Syndrome
- Cytokine Release Syndrome
- Tazemetostat
- (no location specified)
Nov 17, 2021
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Philadelphia (Palbociclib, Tazemetostat,
Not yet recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Palbociclib
- +4 more
-
Philadelphia, PennsylvaniaThomas Jefferson University Hospital
Jan 13, 2023
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Trial in Japan (Tazemetostat)
Completed
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- Tazemetostat
-
Nagoya, Aichi, Japan
- +27 more
Nov 18, 2022
All Malignancies, Advanced Malignancies, Hematologic Malignancy Trial in Spain, United States (Tazemetostat, Itraconazole,
Active, not recruiting
- All Malignancies
- +11 more
- Tazemetostat
- +2 more
-
Encinitas, California
- +9 more
May 20, 2022
B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2) Trial in Worldwide
Completed
- B-cell Lymphomas (Phase 1)
- +5 more
- Tazemetostat
-
Birmingham, Alabama
- +51 more
Dec 8, 2021
Follicular Lymphoma Trial in United States (Tazemetostat, Rituximab)
Recruiting
- Follicular Lymphoma
- Tazemetostat
- Rituximab
-
Birmingham, Alabama
- +19 more
Mar 29, 2022
Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT) Trial in
Active, not recruiting
- Malignant Rhabdoid Tumors (MRT)
- +10 more
- Tazemetostat
-
San Francisco, California
- +31 more
Jan 17, 2023